Journal article

Resveratrol inhibits release of soluble fms-like tyrosine kinase (sFlt-1) and soluble endoglin and improves vascular dysfunction - implications as a preeclampsia treatment

Natalie J Hannan, Fiona C Brownfoot, Ping Cannon, Minh Deo, Sally Beard, Tuong V Nguyen, Kirsten R Palmer, Stephen Tong, Tu'uhevaha J Kaitu'u-Lino

SCIENTIFIC REPORTS | NATURE PUBLISHING GROUP | Published : 2017

Abstract

Preeclampsia is a disease of pregnancy associated with placental oxidative stress, inflammation and elevated release of anti-angiogenic factors sFlt-1 and soluble endoglin. These placental factors cause generalized maternal endothelial dysfunction. There are no treatments to halt disease progression; delivery is the only cure. Resveratrol modulates pathways involved in inflammation and oxidative stress and may offer a potential therapeutic for preeclampsia. Resveratrol reduced sFlt-1, sFlt-1 e15a and soluble endoglin secretion from primary trophoblasts and HUVECs and reduced mRNA expression of pro-inflammatory molecules NFκB, IL-6 and IL-1β in trophoblasts. IL-6, IL-1β and TNFα secretion wer..

View full abstract